A multicenter retrospective study to evaluate the safety and efficacy of bendamustine–rituximab (BR) in previously untreated patients with chronic lymphocytic leukaemia (CLL).

Trial Profile

A multicenter retrospective study to evaluate the safety and efficacy of bendamustine–rituximab (BR) in previously untreated patients with chronic lymphocytic leukaemia (CLL).

Completed
Phase of Trial: Phase IV

Latest Information Update: 05 May 2016

At a glance

  • Drugs Bendamustine (Primary) ; Rituximab (Primary)
  • Indications Chronic lymphocytic leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 05 May 2016 New trial record
    • 26 Apr 2016 Results published in the European Journal of Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top